ADJUVANT LARGE FIELD IRRADIATION OF MICROMETASTATIC RESIDIUM IN PROSTATECTOMY

前列腺切除术中微转移残留物的辅助大场照射

• 批准号: 2464554
• 负责人: P OKUNIEFF
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2464554
• 关键词: clinical research; cytotoxicity; hormone therapy; human subject; human therapy evaluation; metastasis; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; prostate neoplasms; prostate specific antigen; prostate surgery; quality of life; radiation therapy dosage

At present almost 80% of men with prostate cancer will ultimately face the problem of a rising PSA despite a prostatectomy. The current management of this recurrent cancer is either observation, prostatic bed irradiation or hormnoe therapy. No therapy to date is aimed at curing these patients and the role of any therapy is unknown. We believe that early metastatic recurrence of prostate cancer is localized in a small number of sites, usually limited to the axial skeleton, pelvis, and lung. Based on extensive reviews we have also determined that control of these micrometastases is high after low doses of radiation (30-40 Gy). These doses are known to be well tolerated in Hodgkin's disease patients who also receive extensive chemotherapy with their irradiation. We believe the low dose irradiation of bones and lung will cure a substantial number of patients with rising PSA values. We will also follow quality of life parameters to assure that cures are not accompanied by undo toxicity.

目前，几乎80%的前列腺癌患者最终将面临 前列腺特异性抗原升高的问题 现行管理 这种复发性癌症的治疗方法是观察，前列腺床照射 或激素疗法。 到目前为止，还没有一种治疗方法旨在治愈这些患者。 任何治疗的作用都是未知的。 我们认为早期转移性癌 前列腺癌的复发局限于少数部位， 通常局限于中轴骨骼、骨盆和肺部。基于 广泛的审查，我们还确定，控制这些 在低剂量辐射（30-40戈伊）后微转移是高的。 这些 已知剂量在霍奇金病患者中耐受良好， 也接受广泛的化疗与他们的辐射。 我们认为 骨和肺的低剂量照射将治愈相当多的 PSA值升高的患者。 我们还将遵循生活质量 参数，以确保固化不伴随着还原毒性。